La catena delle opzioni mostra i dati chiave delle opzioni azionarie di EZCORP a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per EZCORP..

EZCORP (NASDAQ:EZPW) Azioni, Catena delle Opzioni

EZCORP INC-CL A

EZCORP

EZCORP Inc is a United States-based company engaged in offering pawn loans in the United States and Mexico. It also offers short-term unsecured loans and other consumer financial products, and buy and sell second-hand goods. The operating segments of the company are us Pawn, Latin America Pawn, and other international. us Pawn segment includes all pawn activities in the United States. Latin America Pawn segment includes all pawn activities in Mexico and other parts of Latin America. The company generates revenue from merchandise sales, jewelry scrapping sales, and pawn service charges, of which key revenue is derived from the merchandise sales which are primarily collateral forfeited from pawn lending operations and used merchandise purchased from the customers.

wall street chart shutter2

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

EZPW

HRTG

Titoli del settore finanziario a rischio correzione nel breve termine. Le strategie per proteggere il portafoglio e massimizzare i profitti.

3 azioni finanziarie che potrebbero crollare ad aprile

EZCORP, Inc. - Class A Non-Voting Common Stock

EZCORP Inc

<p>In the current session, the stock is trading at $15.84, after a <strong>0.37%</strong> spike. Over the past month, <strong>EZCORP Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>)</strong> stock increased by <strong>16.64%</strong>, and in the past year, by <strong>43.67%</strong>. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.</p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1743786033_0.png" alt="Past Year Chart" /></p>

<h3>Comparing EZCORP P/E Against Its Peers</h3>
<p>The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. </p>
<p>Compared to the aggregate P/E ratio of the <strong>18.15</strong> in the Consumer Finance industry, EZCORP Inc. has a lower P/E ratio of <strong>13.84</strong>. Shareholders might be inclined to think that  the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1743786033_1.png" alt="Guage" /></p>

<p>In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes. </p>


Intraday Update

P/E Ratio Insights for EZCORP

<p>As of April 4, 2025, three stocks in the financial sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.</p>
<p>The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. </p>
<p>Here's the latest list of major overbought players in this sector.</p>
<h3 class="wp-block-heading"><strong>Heritage Insurance Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRTG#NYSE">HRTG</a>)</strong></h3>
<ul>
<li>On March 11, Heritage Insurance posted better-than-expected quarterly earnings. &#8220;The year 2024 was marked by numerous destructive hurricanes affecting communities across the Southeastern United States and in 2025, we&#8217;ve seen devastating wildfires affect residents of California,&#8221; said Ernie Garateix, Heritage CEO. The company's stock gained around 35% over the past month and has a 52-week high of $16.90.</li>
<li><strong>RSI Value:</strong> 75.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li><strong>HRTG Price Action:</strong> Shares of Heritage Insurance gained 0.6% to close at $15.62 on Thursday.</li>
<li>Edge Stock Ratings: 94.40 Momentum score with Value at 91.39. </li>
</ul>
<p><figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/HRTG"><img loading="lazy" decoding="async" width="432" height="178" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04042734/image-42.png" alt="" class="wp-image-857066" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04042734/image-42.png 432w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04042734/image-42-300x124.png 300w" sizes="(max-width: 432px) 100vw, 432px" /></a></figure></p>
<h3 class="wp-block-heading"><strong>CME Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>)</strong></h3>
<ul>
<li>On April 2, CME Group reported that average daily volume rose 13% year-over-year in the first quarter. The company's stock gained around 7% over the past month and <a href="https://www.benzinga.com/quote/CME">has a 52-week high</a> of $271.22.</li>
<li><strong>RSI Value:</strong> 71.4</li>
<li><strong>CME Price Action:</strong> Shares of CME gained 2.2% to close at $268.36 on Thursday.</li>
</ul>
<h3 class="wp-block-heading"><strong>EZCORP Inc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>)</h3>
<ul>
<li>On March 28, EZCORP announced the closing of private offering of $300,000,000 of senior notes due 2032. The company's stock gained around 19% over the past month and has a<a href="https://www.benzinga.com/quote/EZPW"> 52-week high</a> of $16.35.</li>
<li><strong>RSI Value:</strong> 76.5</li>
<li><strong>EZPW Price Action:</strong> Shares of EZCORP gained 3% to close at $15.78 on Thursday.</li>
</ul>
<p>Curious about other BZ Edge Rankings? Click here to discover <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how similar stocks measure up</a>. </p>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/04/44641655/guess-simulations-plus-and-3-stocks-to-watch-heading-into-friday">Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday</a></strong> </li>
</ul>
<p><em>Photo via Shutterstock</em></p>


Top 3 Financial Stocks That May Fall Off A Cliff In April

Reported Earlier, EZCORP Announces $300M Senior Notes Offering At 7.375% Interest, Maturing 2032, With Proceeds To Repay Convertible Debt

EZCORP Terminates Acquisition Agreement With Presta Dinero For Purchase Of 53 Stores In Mexico

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li>Lake Street analyst Frank Takkinen initiated coverage on <strong>Axogen, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXGN#NASDAQ">AXGN</a>) with a Buy rating and announced a price target of $30. Axogen shares closed at $17.25 on Friday. <a href="https://www.benzinga.com/quote/AXGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Craig-Hallum analyst John Wilkin initiated coverage on <strong>Personalis, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) with a Buy rating and announced a price target of $8. Personalis shares closed at $3.63 on Friday. <a href="https://www.benzinga.com/quote/PSNL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Andrew Brackmann initiated coverage on <strong>Butterfly Network, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) with an Outperform rating. Butterfly Network shares closed at $2.68 on Friday. <a href="https://www.benzinga.com/quote/BFLY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Roth MKM analyst Craig Irwin initiated coverage on <strong>EZCORP, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) with a Buy rating and announced a price target of $16. EZCORP shares closed at $13.45 on Friday. <a href="https://www.benzinga.com/quote/EZPW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Michael Yee initiated coverage on <strong>Blueprint Medicines Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Buy rating and announced a price target of $135. Blueprint Medicines shares closed at $89.58 on Friday. <a href="https://www.benzinga.com/quote/BPMC/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
<p><strong>Considering buying BPMC stock? Here&#8217;s what analysts think: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></strong></li>
</ul>
<p><em>Photo: Bigc Studio/Shutterstock.com</em></p>


Initiation

Analyst Ratings

AXGN

BFLY

BPMC

PSNL

This Blueprint Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

<p>Roth MKM  analyst Craig Irwin   initiates coverage on EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) with a Buy rating and announces Price Target of $16.</p>


Price Target

Roth MKM Initiates Coverage On EZCORP with Buy Rating, Announces Price Target of $16

<p>A new SEC filing reveals that <strong>Srivatsa Zena Arnold</strong>, Board Member at <strong>EZCORP</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>), made a notable insider purchase on March 14,.</p>
<p><strong>What Happened:</strong> A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000876523/000177703625000002//Archives/edgar/data/876523/000177703625000002/0001777036-25-000002-index.htm">U.S. Securities and Exchange Commission</a> on Friday showed that Arnold purchased 12,725 shares of EZCORP. The total transaction amounted to $170,006. </p>
<p>During Friday's morning session, <strong>EZCORP</strong> shares down by 0.0%, currently priced at $13.14.</p>
<h3>Discovering EZCORP: A Closer Look</h3>
<p>EZCORP Inc is a United States-based company engaged in offering pawn loans in the United States and Mexico. It also offers short-term unsecured loans and other consumer financial products, and buy and sell second-hand goods. The operating segments of the company are us Pawn, Latin America Pawn, and other international. us Pawn segment includes all pawn activities in the United States. Latin America Pawn segment includes all pawn activities in Mexico and other parts of Latin America. The company generates revenue from merchandise sales, jewelry scrapping sales, and pawn service charges, of which key revenue is derived from the merchandise sales which are primarily collateral forfeited from pawn lending operations and used merchandise purchased from the customers.</p>
<h3>A Deep Dive into EZCORP's Financials</h3>
<p><strong>Revenue Growth:</strong> EZCORP's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>6.73%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Analyzing Profitability Metrics:</strong></p>
<ul>
<li>
<p><strong>Gross Margin:</strong> The company issues a cost efficiency warning with a low gross margin of <strong>57.91%</strong>, indicating potential difficulties in maintaining profitability compared to its peers.</p>
</li>
<li>
<p><strong>Earnings per Share (EPS):</strong> EZCORP's EPS reflects a decline, falling below the industry average with a current EPS of <strong>0.57</strong>.</p>
</li>
</ul>
<p><strong>Debt Management:</strong> EZCORP's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.69</strong>.</p>
<p><strong>Financial Valuation:</strong></p>
<ul>
<li>
<p><strong>Price to Earnings (P/E) Ratio:</strong> The current P/E ratio of <strong>11.53</strong> is below industry norms, indicating potential undervaluation and presenting an investment opportunity.</p>
</li>
<li>
<p><strong>Price to Sales (P/S) Ratio:</strong> The Price to Sales ratio is <b><strong>0.93</strong></b>, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.</p>
</li>
<li>
<p><strong>EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization):</strong> EZCORP's EV/EBITDA ratio at <strong>6.74</strong> suggests potential undervaluation, falling below industry averages.</p>
</li>
</ul>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><a href="https://www.schwab.com/brokerage?aff=XEC"><em>Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</em></a></p>
<h3>Why Pay Attention to Insider Transactions</h3>
<p>Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.</p>
<p>Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.</p>
<p>The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.</p>
<p>However, insider sells may not always signal a bearish view and can be influenced by various factors.</p>
<h3>Important Transaction Codes</h3>
<p>Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A <strong>P</strong> in Box 3 denotes a purchase, while <strong>S</strong> signifies a sale. Transaction code <strong>C</strong> denotes the conversion of an option, and transaction code <strong>A</strong> signifies a grant, award, or other acquisition of securities from the company.</p>
<p><a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000876523"><strong>Check Out The Full List Of EZCORP's Insider Trades.</strong></a></p>
<p><strong>Insider Buying Alert: Profit from C-Suite Moves</strong></p>
<p>Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insider Trades

Insider Move: Srivatsa Zena Arnold Invests $170K In EZCORP Stock

<p>Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:</p>
<p><strong>Barclays </strong>BCS: This major global banking and financial services company with more than 325 years of expertise in banking, and operating through an international network in nearly 40 countries and regions in Europe, the U.S., Africa and Asia, the company provides a wide range of financial services to individuals, corporations and institutions, has seen the Zacks Consensus Estimate for its current year earnings increasing 29% over the last 60 days.</p>
<div class="chart_embed">
<h3>Barclays PLC Price and Consensus</h3>
<p><a href="https://www.zacks.com/stock/chart/BCS/price-consensus-chart?icid=chart-BCS-price-consensus-chart"><img alt="Barclays PLC Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/a2/1740650708.png" style="height:283px; width:610px" title="" /> </a></p>
<p><a href="https://www.zacks.com/stock/chart/BCS/price-consensus-chart?icid=chart-BCS-price-consensus-chart">Barclays PLC price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/BCS?icid=chart-BCS-price-consensus-chart">Barclays PLC Quote</a></p>
</div>
<p><strong>CareDx </strong>CDNA: This commercial stage company which develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients, has seen the Zacks Consensus Estimate for its current year earnings increasing 9.3% over the last 60 days.</p>
<div class="chart_embed">
<h3>CareDx, Inc. Price and Consensus</h3>
<p><a href="https://www.zacks.com/stock/chart/CDNA/price-consensus-chart?icid=chart-CDNA-price-consensus-chart"><img alt="CareDx, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/a2/1740650708.png" style="height:282px; width:610px" title="" /> </a></p>
<p><a href="https://www.zacks.com/stock/chart/CDNA/price-consensus-chart?icid=chart-CDNA-price-consensus-chart">CareDx, Inc. price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/CDNA?icid=chart-CDNA-price-consensus-chart">CareDx, Inc. Quote</a></p>
</div>
<p><strong>The Progressive </strong>PGR: This company which is one of the major auto insurers in the country, has seen the Zacks Consensus Estimate for its current year earnings increasing 5.8% over the last 60 day.</p>
<div class="chart_embed">
<h3>The Progressive Corporation Price and Consensus</h3>
<p><a href="https://www.zacks.com/stock/chart/PGR/price-consensus-chart?icid=chart-PGR-price-consensus-chart"><img alt="The Progressive Corporation Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/df/1740650710.png" style="height:278px; width:610px" title="" /> </a></p>
<p><a href="https://www.zacks.com/stock/chart/PGR/price-consensus-chart?icid=chart-PGR-price-consensus-chart">The Progressive Corporation price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/PGR?icid=chart-PGR-price-consensus-chart">The Progressive Corporation Quote</a></p>
</div>
<p><strong>EZCORP </strong>EZPW: This company which is engaged in establishing, acquiring, and operating pawnshops which function as convenient sources of consumer credit and as value-oriented specialty retailers of primarily previously owned merchandise, has seen the Zacks Consensus Estimate for its current year earnings increasing 3.2% over the last 60 days.</p>
<div class="chart_embed">
<h3>EZCORP, Inc. Price and Consensus</h3>
<p><a href="https://www.zacks.com/stock/chart/EZPW/price-consensus-chart?icid=chart-EZPW-price-consensus-chart"><img alt="EZCORP, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/b7/1740650711.png" style="height:283px; width:610px" title="" /> </a></p>
<p><a href="https://www.zacks.com/stock/chart/EZPW/price-consensus-chart?icid=chart-EZPW-price-consensus-chart">EZCORP, Inc. price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/EZPW?icid=chart-EZPW-price-consensus-chart">EZCORP, Inc. Quote</a></p>
</div>
<p><strong>EverQuote </strong>EVER: This company which operates an online marketplace for consumers shopping for auto, home and renters and life insurance, has seen the Zacks Consensus Estimate for its current year earnings increasing 1.3% over the last 60 days.</p>
<div class="chart_embed">
<h3>EverQuote, Inc. Price and Consensus</h3>
<p><a href="https://www.zacks.com/stock/chart/EVER/price-consensus-chart?icid=chart-EVER-price-consensus-chart"><img alt="EverQuote, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/ce/1740650716.png" style="height:282px; width:610px" title="" /> </a></p>
<p><a href="https://www.zacks.com/stock/chart/EVER/price-consensus-chart?icid=chart-EVER-price-consensus-chart">EverQuote, Inc. price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/EVER?icid=chart-EVER-price-consensus-chart">EverQuote, Inc. Quote</a></p>
</div>
<p>&nbsp;</p>
<p>You can see&nbsp;<a href="https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&amp;ICID=zpi%20_1link">the complete list of today&#39;s Zacks #1 Rank (Strong Buy) stocks here</a>.</p>
<p>&nbsp;</p>
<h2>5 Stocks Set to Double</h2>
<p>Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.</p>
<p>Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.</p>
<p><a href="https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1726&amp;adid=SYND_BENZ_ZU_5S2DREPORT_ZACKS1RANKADDITIONS_02272025_2420915&amp;cid=CS-BENZ-FT-zacks_1_rank_additions-2420915" style="font-weight:bold">Today, See These 5 Potential Home Runs &gt;&gt;</a></p>
<p>&nbsp;</p>
<p>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. <a href="https://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&amp;ADID=SYND_BENZ_7BEST_ZACKS1RANKADDITIONS_2420915&amp;cid=CS-BENZ-FT-zacks_1_rank_additions-2420915" target="_blank">Click to get this free report</a></p>
<p>
&nbsp;<br />
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=BCS&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_2420915_BCS&amp;cid=CS-BENZ-FT-zacks_1_rank_additions-2420915">Barclays PLC (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/bcs#NYSE">BCS</a>): Free Stock Analysis Report<br />
&nbsp;<br />
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=PGR&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_2420915_PGR&amp;cid=CS-BENZ-FT-zacks_1_rank_additions-2420915">The Progressive Corporation (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/pgr#NYSE">PGR</a>): Free Stock Analysis Report<br />
&nbsp;<br />
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=EZPW&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_2420915_EZPW&amp;cid=CS-BENZ-FT-zacks_1_rank_additions-2420915">EZCORP, Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/ezpw#NASDAQ">EZPW</a>): Free Stock Analysis Report<br />
&nbsp;<br />
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=EVER&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_2420915_EVER&amp;cid=CS-BENZ-FT-zacks_1_rank_additions-2420915">EverQuote, Inc. (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/ever#NYSE">EVER</a>): Free Stock Analysis Report<br />
&nbsp;<br />
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=CDNA&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_2420915_CDNA&amp;cid=CS-BENZ-FT-zacks_1_rank_additions-2420915">CareDx, Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/cdna#NASDAQ">CDNA</a>): Free Stock Analysis Report</p>
<p><a href="https://www.zacks.com/commentary/2420915/new-strong-buy-stocks-for-february-27th?cid=CS-BENZ-FT-zacks_1_rank_additions-2420915">This article originally published on Zacks Investment Research (zacks.com).</a></p>
<p><a href="https://www.zacks.com/">Zacks Investment Research</a></p>


Equities

Fintech news covering the emerging Financial Technology services sector

Fintech

Tech

CDNA

EVER

New Strong Buy Stocks For February 27th

<p>Here are three stocks with buy rank and strong value characteristics for investors to consider today, February 11th:</p>
<p><strong>OMV Aktiengesellschaft </strong>OMVKY: This energy and chemicals company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.5% over the last 60 days.</p>
<div class="chart_embed">
<h3>OMV AG Price and Consensus</h3>
<p><a href="https://www.zacks.com/stock/chart/OMVKY/price-consensus-chart?icid=chart-OMVKY-price-consensus-chart"><img alt="OMV AG Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/f0/1739262717.png" style="height:264px; width:527px" title="" /> </a></p>
<p><a href="https://www.zacks.com/stock/chart/OMVKY/price-consensus-chart?icid=chart-OMVKY-price-consensus-chart">OMV AG price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/OMVKY?icid=chart-OMVKY-price-consensus-chart">OMV AG Quote</a></p>
</div>
<p>OMV has a price-to-earnings ratio (P/E) of 5.96, compared with 7.30 for the industry. The company possesses a <a href="https://www.zacks.com/style-scores-education/">Value Score</a>&nbsp; of A.</p>
<div class="chart_embed">
<h3>OMV AG PE Ratio (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ttm#NYSE">TTM</a>)</h3>
<p><a href="https://www.zacks.com/stock/chart/OMVKY/fundamental/pe-ratio-ttm?icid=chart-OMVKY-fundamental/pe-ratio-ttm">TTM</a>)&quot; height=&quot;250&quot; src=&quot;https://staticx-tuner.zacks.com/images/charts/c9/1739262943.png&quot; title=&quot;&quot; width=&quot;493&quot; /&gt;</p>
<p><a href="https://www.zacks.com/stock/chart/OMVKY/fundamental/pe-ratio-ttm?icid=chart-OMVKY-fundamental/pe-ratio-ttm">OMV AG pe-ratio-ttm</a> | <a href="https://www.zacks.com/stock/quote/OMVKY?icid=chart-OMVKY-fundamental/pe-ratio-ttm">OMV AG Quote</a></p>
</div>
<p><strong>Pacira BioSciences, Inc. </strong>PCRX: This non-opioid pain management and regenerative health solutions company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its next year earnings increasing 21% over the last 60 days.</p>
<div class="chart_embed">
<h3>Pacira BioSciences, Inc. Price and Consensus</h3>
<p><a href="https://www.zacks.com/stock/chart/PCRX/price-consensus-chart?icid=chart-PCRX-price-consensus-chart"><img alt="Pacira BioSciences, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/18/1739262729.png" style="height:264px; width:568px" title="" /> </a></p>
<p><a href="https://www.zacks.com/stock/chart/PCRX/price-consensus-chart?icid=chart-PCRX-price-consensus-chart">Pacira BioSciences, Inc. price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/PCRX?icid=chart-PCRX-price-consensus-chart">Pacira BioSciences, Inc. Quote</a></p>
</div>
<p>Pacira has a price-to-earnings ratio (P/E) of 7.69, compared with 24.45 for the S&amp;P 500. The company possesses a Value Score of A.</p>
<div class="chart_embed">
<h3>Pacira BioSciences, Inc. PE Ratio (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ttm#NYSE">TTM</a>)</h3>
<p><a href="https://www.zacks.com/stock/chart/PCRX/fundamental/pe-ratio-ttm?icid=chart-PCRX-fundamental/pe-ratio-ttm">TTM</a>)&quot; height=&quot;250&quot; src=&quot;https://staticx-tuner.zacks.com/images/charts/35/1739262962.png&quot; title=&quot;&quot; width=&quot;527&quot; /&gt;</p>
<p><a href="https://www.zacks.com/stock/chart/PCRX/fundamental/pe-ratio-ttm?icid=chart-PCRX-fundamental/pe-ratio-ttm">Pacira BioSciences, Inc. pe-ratio-ttm</a> | <a href="https://www.zacks.com/stock/quote/PCRX?icid=chart-PCRX-fundamental/pe-ratio-ttm">Pacira BioSciences, Inc. Quote</a></p>
</div>
<p><strong>EZCORP, Inc. </strong>EZPW: This pawn services company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.2% over the last 60 days.</p>
<div class="chart_embed">
<h3>EZCORP, Inc. Price and Consensus</h3>
<p><a href="https://www.zacks.com/stock/chart/EZPW/price-consensus-chart?icid=chart-EZPW-price-consensus-chart"><img alt="EZCORP, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/f4/1739262742.png" style="height:264px; width:568px" title="" /> </a></p>
<p><a href="https://www.zacks.com/stock/chart/EZPW/price-consensus-chart?icid=chart-EZPW-price-consensus-chart">EZCORP, Inc. price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/EZPW?icid=chart-EZPW-price-consensus-chart">EZCORP, Inc. Quote</a></p>
</div>
<p>Ezcorp has a price-to-earnings ratio (P/E) of 10.33, compared with 15.30 for the industry. The company possesses a Value Score of A.</p>
<div class="chart_embed">
<h3>EZCORP, Inc. PE Ratio (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ttm#NYSE">TTM</a>)</h3>
<p><a href="https://www.zacks.com/stock/chart/EZPW/fundamental/pe-ratio-ttm?icid=chart-EZPW-fundamental/pe-ratio-ttm">TTM</a>)&quot; height=&quot;251&quot; src=&quot;https://staticx-tuner.zacks.com/images/charts/b8/1739262981.png&quot; title=&quot;&quot; width=&quot;532&quot; /&gt;</p>
<p><a href="https://www.zacks.com/stock/chart/EZPW/fundamental/pe-ratio-ttm?icid=chart-EZPW-fundamental/pe-ratio-ttm">EZCORP, Inc. pe-ratio-ttm</a> | <a href="https://www.zacks.com/stock/quote/EZPW?icid=chart-EZPW-fundamental/pe-ratio-ttm">EZCORP, Inc. Quote</a></p>
</div>
<p>&nbsp;</p>
<p>See <a href="https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&amp;ICID=zpi%20_1link">the full list of top ranked stocks here.</a></p>
<p>&nbsp;</p>
<p>Learn more about the <a href="https://www.zacks.com/education/stock-scorecard/value-trading">Value score and how it is calculated here.</a></p>
<p>&nbsp;</p>
<h2>Only $1 to See All Zacks&#39; Buys and Sells</h2>
<p><em>We&#39;re not kidding.</em></p>
<p>Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.</p>
<p>Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like&nbsp;<em>Surprise Trader, Stocks Under $10, Technology Innovators,</em>and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.</p>
<p><a href="https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/6328?adid=SYND_BENZ_ZU_ZU_ZACKS1RANKADDITIONS_268_02112025_2413286&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2413286" style="font-weight:bold">See Stocks Now &gt;&gt;</a></p>
<p>&nbsp;</p>
<p>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. <a href="https://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&amp;ADID=SYND_BENZ_7BEST_ZACKS1RANKADDITIONS_268_2413286&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2413286" target="_blank">Click to get this free report</a></p>
<p>
&nbsp;<br />
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=EZPW&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_268_2413286_EZPW&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2413286">EZCORP, Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/ezpw#NASDAQ">EZPW</a>): Free Stock Analysis Report<br />
&nbsp;<br />
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=PCRX&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_268_2413286_PCRX&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2413286">Pacira BioSciences, Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/pcrx#NASDAQ">PCRX</a>): Free Stock Analysis Report<br />
&nbsp;<br />
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=OMVKY&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_268_2413286_OMVKY&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2413286">OMV AG (OMVKY): Free Stock Analysis Report</a></p>
<p><a href="https://www.zacks.com/commentary/2413286/best-value-stocks-to-buy-for-february-11th?cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2413286">To read this article on Zacks.com click here.</a></p>
<p><a href="https://www.zacks.com/">Zacks Investment Research</a></p>


Small Cap

PCRX

Best Value Stocks To Buy For February 11th

<p>Canaccord Genuity  analyst Brian McNamara   maintains EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) with a Buy and raises the price target from $19 to $22.</p>


Canaccord Genuity Maintains Buy on EZCORP, Raises Price Target to $22

<p>Stephens &amp; Co.  analyst Kyle Joseph   reiterates EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) with a Equal-Weight and maintains $13.5 price target.</p>


Reiteration

Stephens & Co. Reiterates Equal-Weight on EZCORP, Maintains $13.5 Price Target

<p>The earnings results for <strong>EZCORP</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) for Q1 were made public on Wednesday, February 5, 2025 at 04:48 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>EZCORP beat estimated earnings by 14.000000000000002%, reporting an EPS of $0.42 versus an estimate of $0.37.</p>
<p>Revenue was up $20.18 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>The company missed on EPS by $0.0 in the last quarter, resulting in a 1.0% increase share price change the following day.</p>
<p>Here's a look at EZCORP's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.26</td>
<td>0.21</td>
<td>0.25</td>
<td>0.28</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.26</td>
<td>0.23</td>
<td>0.28</td>
<td>0.36</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>288.49M</td>
<td>279.55M</td>
<td>282.19M</td>
<td>296.13M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>294.55M</td>
<td>281.42M</td>
<td>285.64M</td>
<td>299.99M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for EZCORP <a href="https://www.benzinga.com/quote/EZPW/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

EZCORP Q1 Earnings Report: What Investors Need to Know

<p>EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.37 by 13.51 percent. This is a 16.67 percent increase over earnings of $0.36 per share from the same period last year.  The company reported quarterly sales of $320.200 which missed the analyst consensus estimate of $322.828 million by 100.00 percent.  This is a 100.00 percent decrease over sales of $299.991 million the same period last year.</p>


Earnings Beats

Earnings Misses

EZCORP Q1 2025 Adj. EPS $0.42 Beats $0.37 Estimate, Sales $320.200 Miss $322.828M Estimate

ALGN

AMSC

AOSL

APPS

ARAY

ARCC

ARES

ASGN

ASYS

AZTA

BARK

BLBD

BSBR

CENT

CENTA

CMRE

CNMD

CNXN

COHR

CPAY

CPRI

CRTO

CSGS

CTSH

CTVA

DGII

DLHC

ENSG

EQNR

FORM

GEOS

HOLX

ITUB

KMPR

LFVN

LSAK

LUCK

LVWR

MSTR

MTRX

MUSA

NOTV

NTGR

NVST

NWSA

ODFL

ORLY

PAHC

PFGC

Earnings Scheduled For February 5, 2025

<p>EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) reported quarterly earnings of $0.26 per share which missed the analyst consensus estimate of $0.27 by 3.7 percent.  The company reported quarterly sales of $294.55 million which beat the analyst consensus estimate of $288.49 million by 2.10 percent.  This is a 8.90 percent increase over sales of $270.48 million the same period last year.</p>


EZCORP Q4 2024 Adj EPS $0.26 Misses $0.27 Estimate, Sales $294.55M Beat $288.49M Estimate

<p>Stephens &amp; Co.  analyst Kyle Joseph   initiates coverage on EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) with a Equal-Weight rating and announces Price Target of $13.</p>


Stephens & Co. Initiates Coverage On EZCORP with Equal-Weight Rating, Announces Price Target of $13

ACXP

ADAP

AEMD

AFCG

AFYA

AGRO

AIRJ

ALUR

ALVO

ARCO

ATEX

AYTU

BCDA

BETR

BFRI

BITF

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BNGO

BOXL

BRFS

BWEN

CAAS

CAPR

CREX

CRNT

CSAN

CSCO

CSLR

CSTE

CYBR

DADA

DMAC

DOLE

DRRX

DTCK

ECOR

EDBL

ENLT

FORA

FPAY

FULC

GILT

GLAD

GOEV

GRYP

HIVE

HROW

HYZN

IBTA

ICAD

ICCC

INLX

INVZ

JAGX

JJSF

KBDC

KLIC

KMDA

KRMD

KULR

LMFA

LOAR

LQDA

LUCD

LVLU

MCRB

MPTI

MRSN

NTWK

NXGL

OMER

OPRX

OTRK

OWLT

OXBR

PAVM

PCYO

Earnings Scheduled For November 13, 2024

<p>EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) is preparing to release its quarterly earnings on Wednesday, 2024-11-13. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect EZCORP to report an <strong>earnings per share</strong> (EPS) of $0.26.</p>
<p>The market awaits EZCORP's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>The company's EPS beat by $0.02 in the last quarter, leading to a 0.67% increase in the share price on the following day.</p>
<p>Here's a look at EZCORP's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.21</td>
<td>0.25</td>
<td>0.28</td>
<td>0.17</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.23</td>
<td>0.28</td>
<td>0.36</td>
<td>0.23</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-4.0%</td>
<td>12.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731427318_0.png" alt="eps graph" /></p>
<h3>Market Performance of EZCORP's Stock</h3>
<p>Shares of EZCORP were trading at $11.77 as of November 11. Over the last 52-week period, shares are up 37.05%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Insights on EZCORP</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on EZCORP.</p>
<p>Analysts have provided EZCORP with 1 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $19.0, suggesting a potential 61.43% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of  and EZCORP, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<h3>Insights: Peer Analysis</h3>
<p>In the peer analysis summary, key metrics for  and EZCORP are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>EZCORP</td>
<td>Buy</td>
<td>10.01%</td>
<td>$166.73M</td>
<td>2.24%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>EZCORP is positioned at the bottom for Revenue Growth among its peers. In terms of Gross Profit, EZCORP is also at the bottom compared to its peers. However, EZCORP is at the top for Return on Equity among its peers.</p>
<h3>Delving into EZCORP's Background</h3>
<p>EZCORP Inc is a United States-based company engaged in offering pawn loans in the United States and Mexico. It also offers short-term unsecured loans and other consumer financial products, and buy and sell second-hand goods. The operating segments of the company are us Pawn, Latin America Pawn, and other international. us Pawn segment includes all pawn activities in the United States. Latin America Pawn segment includes all pawn activities in Mexico and other parts of Latin America. The company generates revenue from merchandise sales, jewelry scrapping sales, and pawn service charges, of which key revenue is derived from the merchandise sales which are primarily collateral forfeited from pawn lending operations and used merchandise purchased from the customers.</p>
<h3>A Deep Dive into EZCORP's Financials</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, EZCORP showcased positive performance, achieving a revenue growth rate of <strong>10.01%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> EZCORP's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>6.38%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> EZCORP's ROE excels beyond industry benchmarks, reaching <strong>2.24%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> EZCORP's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.19%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.76</strong>, EZCORP adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/EZPW/earnings"><strong>To track all earnings releases for EZCORP visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Preview For EZCORP

<p>Canaccord Genuity  analyst Brian McNamara   maintains EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) with a Buy and maintains $19 price target.</p>


Canaccord Genuity Maintains Buy on EZCORP, Maintains $19 Price Target

EZCORP To Acquire 53 Pawn Stores From Presta Dinero; Financial Terms Not Disclosed

Press Releases

EZCORP Announces Agreement to Acquire 53 Pawn Stores in Mexico

Comments

EZCORP

EZCORP (EZPW) Opzioni

EZCORP (NASDAQ:EZPW) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO